Correspondingly, for T1DM, a post hoc analysis of the DEPICT‐1/‐2 trials in patients with existing albuminuria at baseline demonstrated that application of dapagliflozin (10 mg) as an adjunct therapy to insulin resulted in a significantly reduced percent change in UACR.56 The gene discussed is INS; the disease is type 1 diabetes mellitus.